Cessatech A/S Logo

Cessatech A/S

Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.

CESSA | SPGR

Overview

Corporate Details

ISIN(s):
DK0061411964
LEI:
549300WO5SKVXWPOXR16
Country:
Denmark
Address:
Kanonbådsvej 2, 1437 København K
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cessatech A/S is a pharmaceutical company specializing in the development and commercialization of evidence-based medicines for children. The company focuses on addressing unmet needs in pediatric care, particularly the treatment of acute pain. Its lead asset, CT001, is a non-invasive analgesic nasal spray for children aged 1-17 undergoing painful medical procedures. This product is designed as an alternative to traditional pain management solutions, such as intravenous injections, which can be distressing for young patients. Originating as a spinout project from Rigshospitalet, Cessatech's business model centers on developing drugs with a potentially shortened time-to-market. The management team has a proven track record in drug development, paediatric research, and global product launches.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cessatech A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cessatech A/S

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cessatech A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AGIOS PHARMACEUTICALS, INC. Logo
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America AGIO
AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America ALGS

Talk to a Data Expert

Have a question? We'll get back to you promptly.